Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - Shire plc | dp64643_8k.htm |
Exhibit 99.1
| Press Release |  |
www.shire.com |
Director/PDMR Shareholding
March 31, 2016 – Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”) announces that Ordinary Shares (“Shares”) and American Depositary Shares (“ADSs”) in the Company, as set out below, have been acquired today for the Non-Executive Directors, being the part of their total fees that are paid in shares for the period of service from January 1 to March 31, 2016.
| Type of Security (1) | Number of Shares/ADSs | ||
| Dominic Blakemore | Shares | 150 | |
| Olivier Bohuon | Shares | 133 | |
| William Burns | Shares | 176 | |
| Dr. Steven Gillis | ADSs | 57 | |
| Dr. David Ginsburg | ADSs | 54 | |
| David Kappler | Shares | 166 | |
| Susan Kilsby | ADSs | 167 | |
| Sara Mathew | ADSs | 53 | |
| Anne Minto | Shares | 170 | |
(1) One ADS is equal to three Shares.
The Shares and ADSs were acquired on the London Stock Exchange and NASDAQ respectively at £39.0774 per Share and $168.9564 per ADS.
This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a) of the Disclosure Rules and Transparency Rules.
Oliver Strawbridge
Senior Assistant Company Secretary
For further information please contact:
| Investor Relations | ||
| Sarah Elton-Farr | seltonfarr@shire.com | +44 1256 894157 |
NOTES TO EDITORS
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.
We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.
www.shire.com
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX